Developments in checkpoint immunotherapy
Developments in checkpoint immunotherapy
Targetted medicine to reduce melanoma mutational burden
VISMO trial to treat basal cell carcinoma
Checkpoint inhibitor therapy for treating melanoma
Connections in cancer-host immune signalling
A global perspective on infections related to cancer
Editor's ASCO 2016 Roundup
Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma
MyPathway guidance of targeted therapy based on molecular profiles
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity
Understanding personalised medicine - the e-learning course